Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
274.2 CHF | +15.51% | -0.47% | -8.62% |
14:10 | Roches Augentherapie Vabysmo erhält grünes Licht des EU-Gremiums für zusätzliche Indikation | MT |
13:36 | Roche-Medikamente Piasky und Vabysmo erhalten positive CHMP-Empfehlungen | AW |
Kurzporträt
Umsatz nach Geschäftsbereich
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Pharmaceuticals
76,6
%
| 48 628 | 73,2 % | 46 279 | 76,6 % | -4.83% |
Diagnostics
23,4
%
| 17 798 | 26,8 % | 14 162 | 23,4 % | -20.43% |
Umsatz je Region
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
46,9
%
| 29 313 | 44,1 % | 28 352 | 46,9 % | -3.28% |
Rest of Europe
16,1
%
| 10 328 | 15,5 % | 9 703 | 16,1 % | -6.05% |
Rest of Asia
14,7
%
| 9 852 | 14,8 % | 8 890 | 14,7 % | -9.76% |
Japan
7,4
%
| 6 452 | 9,7 % | 4 464 | 7,4 % | -30.81% |
Latin America
4,9
%
| 2 870 | 4,3 % | 2 971 | 4,9 % | +3.52% |
Germany
4,8
%
| 3 318 | 5,0 % | 2 893 | 4,8 % | -12.81% |
Africa, Australia and Oceania
2,0
%
| 1 520 | 2,3 % | 1 212 | 2,0 % | -20.26% |
Switzerland
1,8
%
| 1 671 | 2,5 % | 1 118 | 1,8 % | -33.09% |
Rest of North America
1,4
%
| 1 102 | 1,7 % | 838 | 1,4 % | -23.96% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 49 | 01.01.03 | |
Severin Schwan
CHM | Chairman | 57 | 01.01.08 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01.04.11 |
Pascale Schmidt
CMP | Compliance Officer | 51 | 01.01.20 |
Levi Garraway
CTO | Chief Tech/Sci/R&D Officer | - | - |
Bruno Eschli
IRC | Investor Relations Contact | - | - |
Silke Hörnstein
PRN | Corporate Officer/Principal | 49 | 01.01.15 |
Annette Luther
SEC | Corporate Secretary | 54 | 01.04.20 |
General Counsel | 60 | 01.04.20 | |
Human Resources Officer | 57 | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03.03.15 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 01.01.96 | |
Patrick Frost
BRD | Director/Board Member | 56 | 17.03.20 |
Hans Clevers
PRN | Corporate Officer/Principal | 67 | 05.03.19 |
Severin Schwan
CHM | Chairman | 57 | 01.01.08 |
Anita Hauser
BRD | Director/Board Member | 55 | 14.03.17 |
Director/Board Member | 71 | 03.03.15 | |
Director/Board Member | 58 | 01.03.16 | |
Joerg Duschmale
BRD | Director/Board Member | 40 | 17.03.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 106 691 000 | 28 989 189 ( 27,17 %) | 0 | 88,91 % |
Aktie B | 1 | 702 562 700 | 690 549 674 ( 98,29 %) | 12 011 755 ( 1,710 %) |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
1 005 670 000 | 59,89% | 30 596 634 817 $ | |
ROCHE HOLDING AG 1,43% | 10 073 029 | 1,43% | 2 579 249 239 $ |
2 744 120 | 7,42% | 42 451 536 $ | |
454 961 | 3,02% | 11 810 788 $ | |
ALIGOS THERAPEUTICS, INC. 14,70% | 11 025 941 | 14,70% | 6 505 305 $ |
1 893 | 0,06% | 1 609 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Viewics India Pvt Ltd.
| |
Roche Financial Investments Ltd.
| |
Roche Diagnostics Belgium NV
Roche Diagnostics Belgium NV BiotechnologyHealth Technology Part of Roche Holding AG, Roche Diagnostics Belgium NV is a Belgian company that develops innovative products and services for the prevention, diagnosis, monitoring, screening, and treatment of diseases. Roche Diagnostics Belgium is based in Diegem, Belgium, and was founded in 1958. The company offers next-generation sequencing products and in vitro diagnostics that are an integral part of decision-making along the entire continuum of a patient's health or disease. The CEO is Thomas Schinecker. |
Biotechnology
|
Roche Finance Europe BV
|
Finance/Rental/Leasing
|
Roche Financial Management Ltd.
| |
Roche Catalyst Investments Ltd.
| |
Roche Intertrade Ltd.
| |
Roche Pharmholding BV
Roche Pharmholding BV Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Pharmholding BV is a Dutch company that manufactures and distributes pharmaceutical and vitamin products. The company is based in Woerden, Netherlands. |
Medical Distributors
|
Sapac Corp. Ltd.
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+56.66% | 819 Mrd. | |
-6.84% | 351 Mrd. | |
+19.60% | 329 Mrd. | |
+9.11% | 298 Mrd. | |
+17.28% | 242 Mrd. | |
+13.43% | 217 Mrd. | |
+9.42% | 168 Mrd. | |
-2.99% | 158 Mrd. | |
+0.49% | 120 Mrd. |
- Börse
- Aktien
- 855167 Aktie
- 851311 Aktie
- Unternehmen Roche Holding AG